These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
143 related items for PubMed ID: 39380960
1. [18F]NaF PET/CT imaging of response to single fraction SABR to bone metastases from breast cancer. Hardcastle N, Liu Y, Siva S, David S. Front Nucl Med; 2023; 3():1197397. PubMed ID: 39380960 [Abstract] [Full Text] [Related]
2. NaF PET/CT for response assessment of prostate cancer bone metastases treated with single fraction stereotactic ablative body radiotherapy. Hardcastle N, Hofman MS, Lee CY, Callahan J, Selbie L, Foroudi F, Shaw M, Chander S, Lim A, Chesson B, Murphy DG, Kron T, Siva S. Radiat Oncol; 2019 Sep 05; 14(1):164. PubMed ID: 31488175 [Abstract] [Full Text] [Related]
5. The value of baseline 18F-sodium fluoride and 18F-choline PET activity for identifying responders to radium-223 treatment in castration-resistant prostate cancer bone metastases. Donners R, Tunariu N, Tovey H, Hall E, Chua S, Cook G, Du Y, Blackledge MD, Parker CC, Koh DM. Eur Radiol; 2024 Feb 05; 34(2):1146-1154. PubMed ID: 37615760 [Abstract] [Full Text] [Related]
6. Respiratory-gated (4D) FDG-PET detects tumour and normal lung response after stereotactic radiotherapy for pulmonary metastases. Siva S, Callahan JW, Kron T, Chesson B, Barnett SA, Macmanus MP, Hicks RJ, Ball DL. Acta Oncol; 2015 Feb 05; 54(8):1105-12. PubMed ID: 25833329 [Abstract] [Full Text] [Related]
8. Comparison of [68Ga]Ga-PSMA-11 PET/CT with [18F]NaF PET/CT in the evaluation of bone metastases in metastatic prostate cancer patients prior to radionuclide therapy. Uprimny C, Svirydenka A, Fritz J, Kroiss AS, Nilica B, Decristoforo C, Haubner R, von Guggenberg E, Buxbaum S, Horninger W, Virgolini IJ. Eur J Nucl Med Mol Imaging; 2018 Oct 05; 45(11):1873-1883. PubMed ID: 29766246 [Abstract] [Full Text] [Related]
14. Prospective study evaluating the relative sensitivity of 18F-NaF PET/CT for detecting skeletal metastases from renal cell carcinoma in comparison to multidetector CT and 99mTc-MDP bone scintigraphy, using an adaptive trial design. Gerety EL, Lawrence EM, Wason J, Yan H, Hilborne S, Buscombe J, Cheow HK, Shaw AS, Bird N, Fife K, Heard S, Lomas DJ, Matakidou A, Soloviev D, Eisen T, Gallagher FA. Ann Oncol; 2015 Oct 05; 26(10):2113-8. PubMed ID: 26202597 [Abstract] [Full Text] [Related]
17. Review of the role of MRI and 18 F-sodium fluoride PET/computed tomography in the characterisation of spinal bone metastases in a cohort of patients with breast cancer. Panagiotidis E, Pant V, Vinjamuri S. Nucl Med Commun; 2023 Mar 01; 44(3):219-225. PubMed ID: 36592000 [Abstract] [Full Text] [Related]
18. Intra-individual comparison of 18F-sodium fluoride PET-CT and 99mTc bone scintigraphy with SPECT in patients with prostate cancer or breast cancer at high risk for skeletal metastases (MITNEC-A1): a multicentre, phase 3 trial. Bénard F, Harsini S, Wilson D, Zukotynski K, Abikhzer G, Turcotte E, Cossette M, Metser U, Romsa J, Martin M, Mar C, Saad F, Soucy JP, Eigl BJ, Black P, Krauze A, Burrell S, Nichol A, Tardif JC. Lancet Oncol; 2022 Dec 01; 23(12):1499-1507. PubMed ID: 36343655 [Abstract] [Full Text] [Related]